ACM
ALT icon

Atika Capital Management’s Altimmune ALT Stock Holding History

Atika Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-411,039
Closed -$4.81M – 92
2022
Q2 		$4.81M Buy
+411,039
New +$2.53M 0.54% 54

Other funds holding ALT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Atika Capital Management's ALT Position: Q3 2022 in Review

Atika Capital Management sold out of Altimmune (ALT) in Q3 2022, closing a stake of 411,039 shares — an estimated $4.81M sold.

Atika Capital Management first reported a position in ALT in Q2 2022 and held it in 1 quarter. The position peaked at $4.81M in Q2 2022. 122 funds tracked by Wall St. Rank hold ALT as of Q3 2022.

  • Atika Capital Management reported no remaining Altimmune position as of Q3 2022 after selling out during the quarter.
  • Atika Capital Management sold 411,039 Altimmune shares in Q3 2022, an estimated $4.81M.
  • Atika Capital Management first reported a position in Altimmune in Q2 2022 and held it in 1 quarter.
  • Atika Capital Management's Altimmune position peaked at $4.81M in Q2 2022.
  • 122 funds tracked by Wall St. Rank held Altimmune as of Q3 2022.

Based on Atika Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.